Gossamer Bio
GOSS | NASDAQ
$10.98
+$0.01 (+0.09%)
At close: Nov 16, 2026, 4:00 PM ET
$10.98
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:39 PM ET
+0.09%
(1D)No price chart data available for 1D timeframe.
Rating
41.5
Fundamentals Average
Market Sentiment Bullish
Moat None
Sector Rank #480/1021 (Top 47%)
Key Statistics
Market Data
Market Cap $71.7M
1D Range
10.76 11.30
52W Range
8.43 303.20
Valuation (TTM)
PE -0.24
PB -0.58
EV/EBITDA -0.30
Valuation (NTM)
Forward PE N/A
Forward PEG 0.00
Price Target $32.00
Cash Flow
FCF Yield -217.6%
SBC Adj. FCF Yield -239.2%
SBC Impact -9.9%
Margins
Gross Margin 99.7%
Operating Margin -140.0%
FCF Margin -199.0%
Growth (CAGR)
Revenue 3Y | 5Y -17.7% |
44.1%
Dil EPS 3Y | 5Y -24.4% |
45.8%
FCF 3Y | 5Y -73.4% |
4.7%
Returns
ROA -194.4%
ROE 99.8%
ROIC -4305.6%
Financial Health
Net Cash
$14.04M
Current Ratio 0.60
Interest Coverage -10.28
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in...
Sector Healthcare
Industry Biotechnology
Employees 162
IPO Date Feb 8, 2019
Website www.gossamerbio.com
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Nov 10, 2026
EPS
-$7.36
Miss -94.20%
YoY:
+56.19% REV
$38.43M
Beat +216.00%
YoY:
+189.09%Next Earnings
Mar 12, 2027
EPS Est
Pro
Rev Est
Pro
Analyst Summary
# of Analysts
8
Consensus
Buy
Price Target
$32.00
Upside
+191.44%
Buy (5)
Hold (2)
Sell (1)
Add to Watchlist
Select watchlists to add or remove GOSS